Skip to main content

Millennium Sees Revenue Growth in Q4

NEW YORK, Jan. 28 - Millennium Pharmaceuticals today reported increased revenue for the fourth quarter of 2002.

 

The company said its total revenue was $96.8 million in the fourth quarter which ended December 31, up from $54.6.8 million in the same quarter of 2001. Total revenue for the 2002 year was $353 million, compared to $246 million in 2001, according to the company.

 

Millennium reported a net loss based on generally accepted accounting principles of $79.7 million, or $.28 per share, in the fourth quarter of 2002 compared to a net loss of $67 million, or $.30 per share, in the year-ago period. Total net loss for 2002 was $590 million, or $2.13 per share, compared to a net loss of $192 million, or $.88 per share, in 2001.

 

R&D spending for the fourth quarter 2002 was $146.9 million compared to $114.6 million in the same period a year ago. Total R&D spending for 2002 was $511.2 million compared to $400.6 million in 2001. Millennium said the year-over-year increase in R&D was due to expenses related to clinical testing of several of lead compounds.

 

Millennium also reported $1.8 billion in cash, cash equivalents, and marketable securities at the end of December 2002.

 

Millennium merged with COR Therapeutics in February 2002.

 

Click here for more information.

 

 

 

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.